ReviewBreathe (Sheffield, England)2021
The clinical impact of adherence to therapy in airways disease.
Review in Breathe (Sheffield, England), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 13 citations in OpenAlex.
- Cost-Effectiveness of Single- versus Multiple-Inhaler Triple Therapy in a UK COPD Population: The INTREPID Trial.International journal of chronic obstructive pulmonary disease · 2022Trial
- Adherence to asthma medication and asthma control in Finland.BMC pulmonary medicine · 2026Article
- Medication burden, adherence and health-related quality of life in COPD in China: a multilevel health system study.BMJ public health · 2026Article
- Targeted self-directed learning can support clinicians to improve patient adherence to inhaled corticosteroid therapy in asthma.BMJ open respiratory research · 2025Article
- Cost-Effectiveness of Single-Inhaler Versus Multiple-Inhaler Triple Therapy in COPD: A German Healthcare Perspective.International journal of chronic obstructive pulmonary disease · 2025Article
- Does inhaler adherence really matter in severe asthma?Breathe (Sheffield, England) · 2024Review
- Neglecting the neglected: Tobacco cessation support is essential for the management of asthma and COPD.Tobacco induced diseases · 2024Article
- The role of the clinical pharmacist in the respiratory or sleep multidisciplinary team.Breathe (Sheffield, England) · 2023Review
- Advancing Digital Solutions to Overcome Longstanding Barriers in Asthma and COPD Management.Patient preference and adherence · 2023Review
- Adherence to treatment.Breathe (Sheffield, England) · 2021Article
- Measuring adherence to therapy in airways disease.Breathe (Sheffield, England) · 2021Review
- Improving adherence in chronic airways disease: are we doing it wrongly?Breathe (Sheffield, England) · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
For a physician, the final step of a consultation consists of developing a treatment plan and prescription. For the patient, this is the start of a process. First, their role in the treatment plan must be clarified, then they may have to obtain an alternative prescription from their general practitioner. Next, they must have the prescription filled and dispensed from the pharmacy and, finally, they must take the treatment on time and for the required duration. For people with chronic conditions, this requires repeatedly returning to the pharmacy for the prescription to be renewed and dispensed. Given that many patients are on multiple treatment regimens and may have poor health literacy, this becomes a complex process and it is not surprising that this can, and frequently does, go wrong. Research shows that when a patient does not adhere to standard asthma or COPD treatment, they report poor control and overuse of rescue β-agonists, experience frequent exacerbations and are often prescribed add-on treatments such as biological agents. In short, poor treatment adherence can manifest in the same way as a refractory condition. These clinical features should prompt a clinician to investigate poor adherence as they might investigate a new blood or radiological finding. Examining a patient's prescription refill records or a digitally enabled inhaler can demonstrate a number of patterns of inhaler use. A small minority regularly use their treatment as prescribed but many appear to be "cluster users": a group of patients who use their treatment correctly when they are unwell, but once some level of personal control is attained, they cease or reduce their use. Others may cease using their treatment because they are not perceiving a benefit or because an alternative condition accounts for their symptoms. In other words, clinicians can consider that treatment adherence is like a clinical sign: something to be investigated so that they may understand the patient's condition better. EDUCATIONAL
aimsTo highlight the clinical consequences of poor adherence to standard treatments for airways diseases.To describe how poor treatment adherence manifests as complications of the condition.To highlight that when a patient does not benefit as might be expected from a treatment, poor adherence should be considered and evaluated for, before more treatment is added.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.